BioSpace News Archive

Late Wednesday, the company said it is looking to facilitate the sale of its business products in development, as well as its technology.

BridgeBio launched Charlotte, N.C.-based ML Bio Solutions to develop the LGMD2i asset BBP-418, a substrate supplementation therapy.

The following tips from a seasoned recruiter can reduce serious ATS-related errors and help increase the value of the time investment.

Shares of Mallinckrodt are down more than 45% in premarket trading after multiple reports indicate the company plans a restructuring in the wake of the opioid crisis that has promoted a number of lawsuits that implicate the company for its sales practices in the United States.

Auris Medical Holding Ltd. announced the appointment of Elmar Schärli, CPA, as new Chief Financial Officer, effective November 1, 2019.

Rentschler Biopharma SE announced its lineup of activities during the BioProcess International (BPI) Conference, being held September 9-12 in Boston, MA during Biotech Week Boston.

Acacia Pharma Group plc announces its unaudited interim results for the six-month period ended 30 June 2019.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission has approved the expanded use of ustekinumab for the treatment of adults with moderately to severely active ulcerative colitis, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.

Royal DSM, a global science-based company active in Nutrition, Health and Sustainable Living celebrates 150 years of fermentation and biotechnology expertise and innovation at its site in Delft, the Netherlands.

Summit Therapeutics plc presented in vivo proof of concept data for its targeted Enterobacteriaceae antibiotics in animal models of sepsis, pneumonia and urinary tract infection.